Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells - PubMed (original) (raw)

Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells

T Frisan et al. Int J Cancer. 2000.

Abstract

We investigated the expression of interferon gamma (IFN-gamma)-regulated subunits and the enzymatic activity of proteasomes purified from tumor-derived and normal B lymphocytes representing different stages of B-cell activation/differentiation. The catalytic beta subunits (Lmp2 and Lmp7) and the regulatory subunits (PA28alpha and PA28beta) were expressed at equally high levels in Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), freshly isolated B-chronic lymphocytic leukemia (B-CLL) cells and normal CD23(-) B lymphocytes. Lmp2 and Lmp7 were selectively down-regulated in germinal center cell-derived Burkitt's lymphoma (BL) and Hodgkin's lymphoma (HD) cell lines. There was a direct correlation between the expression of Lmp2/7 and the chymotrypsin and trypsin-like activities in proteasomes purified from LCLs, BLs and CLL cells, whereas 5 HD cell lines expressing B or T-cell markers exhibited a variable pattern of subunit expression and enzymatic activity. Poor hydrolysis of the fluorogenic substrates by proteasomes from BL cells correlated with a distinct pattern of cleavage of a reference 50mer peptide, production of different sets of degradation products and significantly reduced recovery of a known cytotoxic T-lymphocyte (CTL) target epitope. The enzymatic activity of proteasomes from normal CD23(-) "resting" B lymphocytes resembled that of BL cells in spite of high Lmp2/7 expression. This pattern was not reversed by treatment with the B-cell mitogen, lipopolysaccharide (LPS). The results suggest that different stages of B-cell activation/differentiation are associated with distinct profiles of IFN-gamma-regulated subunit composition and enzymatic activity of the proteasome. This may have important implications for the analysis and manipulation of tumor-specific immune responses.

PubMed Disclaimer

Cited by

Lymphoma: immune evasion strategies.
Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Upadhyay R, et al. Cancers (Basel). 2015 Apr 30;7(2):736-62. doi: 10.3390/cancers7020736. Cancers (Basel). 2015. PMID: 25941795 Free PMC article. Review.
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.
Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B. Papanikolaou X, et al. Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10. Leukemia. 2015. PMID: 25753926 Free PMC article.
Immunoproteasome Function in Normal and Malignant Hematopoiesis.
Tubío-Santamaría N, Ebstein F, Heidel FH, Krüger E. Tubío-Santamaría N, et al. Cells. 2021 Jun 22;10(7):1577. doi: 10.3390/cells10071577. Cells. 2021. PMID: 34206607 Free PMC article. Review.
Functional module search in protein networks based on semantic similarity improves the analysis of proteomics data.
Boyanova D, Nilla S, Klau GW, Dandekar T, Müller T, Dittrich M. Boyanova D, et al. Mol Cell Proteomics. 2014 Jul;13(7):1877-89. doi: 10.1074/mcp.M113.032839. Epub 2014 May 7. Mol Cell Proteomics. 2014. PMID: 24807868 Free PMC article.
Novel N-amidinopiperidine-based proteasome inhibitor preserves dendritic cell functionality and rescues their Th1-polarizing capacity in Ramos-conditioned tumor environment.
Švajger U, Gobec M, Obreza A, Mlinarič-Raščan I. Švajger U, et al. Cancer Immunol Immunother. 2015 Jan;64(1):15-27. doi: 10.1007/s00262-014-1608-x. Epub 2014 Sep 25. Cancer Immunol Immunother. 2015. PMID: 25253531 Free PMC article.

Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells - PubMed (original) (raw)